The Future of Treatment For Type 2 Diabetes

CHANGSHA, China - Sept. 26, 2022 - PRLog -- Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research.

Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation with traditional insulin and a host of other new drugs in the pipeline.

Current status of treatment development of T2DM

In recent years, the prevalence of T2DM has been increasing rapidly worldwide, which has become a serious public health problem worldwide. The short-term goal of T2DM treatment is to control hyperglycemia, so hypoglycemic therapy is the main treatment for T2DM patients. In addition, healthy lifestyle intervention combined with other drugs to prevent complications related to diabetes treatment (https://us.huatengsci.com/news/show/1581.html) will help improve the quality of life and prolong the life of patients with T2DM.

It is noteworthy that along with the successful application of a large number of innovative treatments, such as continuous glucose monitoring, insulin pumps, oral hypoglycemic sodium-glucose co-transport protein 2 (SGLT2) inhibitors, and injectable glucagon-like peptide-1 (GLP-1) agonists, the proportion of patients with good glycemic management has not increased as expected, which may be partly influenced by the accessibility of drugs, patient education, and patient motivation.

Challenge the New Force of Insulin Resistance

Adiponectin, a protein secreted by adipocytes, is closely associated with insulin resistance and obesity. In vivo and in vitro experiments have confirmed that adiponectin has anti-atherosclerotic, anti-diabetic, anti-inflammatory effects, and can prevent the progression of diabetes and cardiovascular diseases. We note that several studies targeting Adiponectin and its derivatives (e.g., PPARγ agonists) are currently underway, with varying levels of glycemic reduction observed with different therapies, but these studies are currently in the preclinical stage.

GLP-1 agonists belong to the entero-insulin class of drugs, which can bring additional benefits beyond glucose-lowering such as weight loss, lower systolic blood pressure, and improved lipid profile, and the results of studies such as LEADER, SUSTAIN-6, and REWIND suggest that the use of GLP-1 agonists may prevent kidney-related adverse events in patients with T2DM.

Conclusion

At present, scientists are trying to provide better glycemic control therapy for diabetic patients through a variety of innovative mechanisms, some of which are likely to eventually succeed and change the status of treatment and management of T2DM..

Huateng Pharma (https://us.huatengsci.com/) has three SGLT-2 inhibitors in development (https://us.huatengsci.com/product/175.html): Dapagliflozin, Canagliflozin and Empagliflozin that used to treat type 2 diabetes. We can also provide CDMO services with sufficient capacity.